Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12681262 | 1.00 | TP53 (0.33) | TP53TSHR | |
| SCHEMBL899054 | 0.90 | TP53 (0.32) | TP53TSHR | |
| SCHEMBL6593979 | 0.86 | — | — | |
| SCHEMBL6591809 | 0.82 | — | — | |
| SCHEMBL6589294 | 0.80 | — | — | |
| SCHEMBL27996548 | 0.80 | LAP3 (0.33) | TP53 | |
| SCHEMBL516159 | 0.79 | TP53 (0.39) | TP53TSHR | |
| SCHEMBL25138883 | 0.78 | — | — | |
| SCHEMBL12943192 | 0.76 | — | — | |
| SCHEMBL1678417 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 277 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260038886-A1 | SULFONE-BASED ELECTROLYTE AND SECONDARY BATTERY COMPRISING SAME | DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-02-05 | — | — | US | claimed |
| US-20250357553-A1 | LITHIUM ION SECONDARY BATTERY AND MANUFACTURING METHOD THEREOF | LG ENERGY SOLUTION LTD (KR) | 2025-11-20 | — | — | US | claimed |
| EP-4510291-A1 | LITHIUM SECONDARY BATTERY AND MANUFACTURING METHOD THEREFOR | LG Energy Solution, Ltd. (KR) | 2025-02-19 | — | — | EP | claimed |
| WO-2024019272-A1 | SULFONE-BASED ELECTROLYTE AND SECONDARY BATTERY COMPRISING SAME | 재단법인대구경북과학기술원 | 2024-01-25 | — | — | WO | claimed |
| WO-2023239074-A1 | LITHIUM SECONDARY BATTERY AND MANUFACTURING METHOD THEREFOR | 주식회사 엘지에너지솔루션 | 2023-12-14 | — | — | WO | claimed |
| CN-116508191-A | Electrochemical cell with specific liquid electrolyte | 尤米科尔公司 | 2023-07-28 | — | — | CN | claimed |
| CN-109496375-B | Electrolyte and electrochemical device | 株式会社村田制作所 | 2022-12-02 | — | — | CN | claimed |
| US-11456485-B2 | Sulfone sulfonylimide combinations for advanced battery chemistries | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2022-09-27 | — | — | US | claimed |
| EP-3477759-B1 | ELECTROLYTE SOLUTION AND ELECTROCHEMICAL DEVICE COMPRISING THE SAME | MURATA MANUFACTURING CO (JP) | 2021-07-07 | — | — | EP | claimed |
| EP-2481760-B1 | INITIATOR SYSTEM FOR CATIONIC POLYMERIZATION AND POLYMERIZATION METHOD USING SAME | CHINA PETROLEUM & CHEM CORP (CN) | 2021-05-05 | — | — | EP | claimed |
| CN-1267472-C | Process for preparing polyarylethers | CYTEC TECH CORP (US) | 2006-08-02 | — | — | CN | claimed |
| CN-1291209-A | Process for preparing polyarylethers | CYTEC TECH CORP (US) | 2001-04-11 | — | — | CN | claimed |
| EP-0138740-B1 | SYNTHETIC RESIN WOUND DRESSING AND METHOD OF MANUFACTURING | ENQUAY PHARMACEUTICAL ASSOCIATES (US) | 1991-03-06 | — | — | EP | claimed |
| EP-0344090-A2 | Synthetic resin matrix system incorporating healing enhancer | ENQUAY PHARMACEUTICAL ASSOCIATES (US) | 1989-11-29 | — | — | EP | claimed |
| US-4857334-A | Synthetic resin matrix system incorporating healing enhancer | ENQUAY PHARMACEUTICAL ASSOCIATES (US) | 1989-08-15 | — | — | US | claimed |
| US-4747845-A | POLYACRYLATES OR POLYACRYLAMIDE WITH SOLVENT AND HYDROGEN BONDING PLASTICIZER | ENQUAY PHARMACEUTICAL ASSOCIATES (US) | 1988-05-31 | — | — | US | claimed |
| US-4725271-A | POLYMER, SOLVENT, HYDROGEN BONDING PLASTICIZER; PREFORMED OR CURED IN SITU; TIMED RELEASE | ENQUAY PHARMACEUTICAL ASSOCIATES (US) | 1988-02-16 | — | — | US | claimed |
| US-4563184-A | POLYHYDROXYETHYL METHACRYLATE, POLYOXYETHYLENE GLYCOL, PLASTICIZER | ENQUAY, INC. | 1986-01-07 | — | — | US | claimed |
| EP-0138740-A2 | Synthetic resin wound dressing and method of manufacturing | ENQUAY PHARMACEUTICAL ASSOCIATES (US) | 1985-04-24 | — | — | EP | claimed |
| US-3933866-A | Process for the manufacture of amino-anthraquinones | CIBA-GEIGY AG (CH) | 1976-01-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260038886-A1 | SULFONE-BASED ELECTROLYTE AND SECONDARY BATTERY COMPRISING SAME | CA3, CA2, SLC9A1 | TP53 1110/4885TSHR 2426/4885 |
| US-11456485-B2 | Sulfone sulfonylimide combinations for advanced battery chemistries | HCN2, NCS1, HCN3 | TP53 852/4885TSHR 1755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.